225Ac-satoreotide

N/A

Report date: 2026/02/06 20:01:23

NMEFirst In Class

Base Information

Drug Name225Ac-satoreotide

Drug Alias Nameactinium (225Ac) satoreotide tetraxetan225Ac-SSO110

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Nuclides > Actinium > 225Ac +[4]

Mechanisms of ActionSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Merkel Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAriceum Therapeutics GmbH

China Registration ClassN/A

Develop Information

Active CompaniesAriceum Therapeutics GmbH

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, Merkel Cell

Other Information

ATC CodeN/A